Dow to develop obesity treatment

APRIL 01, 2004
Susan Farley

In a collaborative arrangement, Dow Chemical Company and NOBEX Corporation will develop a new plant-based peptide to serve as an appetite suppressant to treat obesity. Dow's research has traditionally focused on antibodies, but according to NOBEX director Radha Krishnan, PhD, "Their plantbased approach appealed to us because of the prospects for lower costs, higher expression levels, and higher volume production." The expression of the peptide is expected to take place in plant cell suspension. Once that is successful, the production will be increased and later conjugated to oral administration. Because of the increasing numbers of obese patients in the United States, the manufacturers anticipate a large demand for commercial use.



SHARE THIS SHARE THIS
0

Conference Coverage from ASHP Summer 2017 

Four years after they first launched the Summer Meetings in Minneapolis, Minn., the ASHP 2017 Summer Meetings and Exhibition was in Minneapolis once again.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.